GlassScriptPhysician profile
Leslie Purvis
NPI 1437696150
$1,277.44
in general payments reported to CMS, 2019-2025
26 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $234 · 2022: $256 · 2023: $99.71 · 2024: $257 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $314.25 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $149.98 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $147.92 | 2023-2025 | |
| Axsome Therapeutics, INC. | $87.86 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $75.41 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $65.37 | 2023-2025 | |
| Glaxosmithkline, LLC. | $46.17 | 2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $40.65 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.41 | 2022 | |
| Bausch Health US, LLC | $30.67 | 2022-2023 | Aplenzin |
| Abbott Laboratories | $30.36 | 2022 | |
| Nestle Healthcare Nutrition INC. | $22.91 | 2022 | |
| Exact Sciences Corporation | $19.39 | 2025 | The Cologuard Plus Collection Kit |
| Avion Pharmaceuticals | $18.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.04 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $17.83 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $17.76 | 2022 | |
| Merck Sharp & Dohme LLC | $17.52 | 2025 | Varivax, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $16.89 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.12 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.94 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $14.82 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.55 | 2024 | Trulance, Xifaxan |
| Astellas Pharma US INC | $14.26 | 2025 | Veozah |
| Pharmacosmos Therapeutics INC. | $13.83 | 2024 | Monoferric |
| Janssen Pharmaceuticals, INC | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Purvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.